<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03271281</url>
  </required_header>
  <id_info>
    <org_study_id>AK2017-2</org_study_id>
    <secondary_id>2017-002512-14</secondary_id>
    <nct_id>NCT03271281</nct_id>
  </id_info>
  <brief_title>PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2</brief_title>
  <official_title>PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this non-randomised, prospective study is to investigate the applicability and
      prognostic value of angiogenesis PET/CT with the radioligand 68Ga-NODAGA- E[c(RGDyK)]2 in
      patients with neuroendocrine tumors (NETs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The radioligand 68Ga-NODAGA- E[c(RGDyK)]2 targets the Arg-Gly-Asp (RGD) sequence known to
      bind with the αvβ3 integrin that is expressed on the surface of angiogenic blood vessels or
      tumor cells. The radioligand can be used to visualize tumor angiogenesis using PET/CT.

      A total of 120 NET patients will be subjected to an angiogenesis-PET/CT scan. Follow-up will
      be performed (from the time of the angiogenesis PET/CT) at 6 months for disease specific
      survival (DSS) and a 1 year follow-up for PFS and OS. The uptake of 68Ga-NODAGA-E[c(RGDyK)]2
      (Standardized Uptake Values, SUVmax) in tumor lesions will be quantified as Standardized
      Uptake Values (SUVmax/SUVmean) and compared with PFS, DSS and OS (dichotomized above/below
      median SUVmax and analyzed by Kaplan-Meier).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiogenesis PET/CT imaging of patients with neuroendocrine tumors</measure>
    <time_frame>1 hour</time_frame>
    <description>The radioligand 68Ga-NODAGA-E[c(RGDyK)]2 can be used to visualize neuroendocrine tumors (grade G1-G3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiogenesis PET/CT progonostic factor for progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>The uptake of the 68Ga-NODAGA-E[c(RGDyK)]2 in neuroendocrine tumor lesions (quantified as Standard Uptake Values) is associated with progression free survival (PFS) neuroendocrine tumors (grade G1-G3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenesis PET/CT prognostic factor for overall and disease specific survival</measure>
    <time_frame>12 months</time_frame>
    <description>The uptake of the 68Ga-NODAGA-E[c(RGDyK)]2 in neuroendocrine tumor lesions (quantified as Standard Uptake Values) is associated with overall and disease specific free survival (PFS) neuroendocrine tumors (grade G1-G3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target validation of angiogenesis PET/CT</measure>
    <time_frame>2 weeks</time_frame>
    <description>Uptake of 68Ga-NODAGA-E[c(RGDyK)]2 correlates directly to gene expression of angiogenesis markers αvβ3 integrin and VEGF-A in tumor tissue obtained by biopsies or planned surgery (&lt;2 weeks before/after angiogenesis PET/CT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Experimental: Angiogenesis PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>One injection of 68Ga-NODAGA-E[c(RGDyK)]2</intervention_name>
    <description>One injection of 68Ga-NODAGA-E[c(RGDyK)]2</description>
    <arm_group_label>Experimental: Angiogenesis PET/CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>Following injection of 68Ga-NODAGA-E[c(RGDyK)]2 the patients will be subjected to whole body PET/CT</description>
    <arm_group_label>Experimental: Angiogenesis PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with gastro-entero-pancreatic Neuroendocrine Tumors (GEP-NET; grade: G1-G3)
             or broncho-pulmonary NET.

          -  WHO performance status 0-2

          -  Must be able to read and understand the patient information in Danish and to give
             informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Breast-feeding

          -  Weight more than the maximum weight limit for the PET/CT bed of the scanner (140 kg)

          -  History of allergic reaction attributable to compounds of similar chemical or biologic
             composition to 68Ga-NODAGA-E[c(RGDyK)]2

          -  In case of broncho-pulmonary NET, the subtype must not be small cell lung cancer
             (SCLC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorthe Skovgaard, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorthe Skovgaard, MD, Phd</last_name>
    <phone>+4535455209</phone>
    <email>dorthe.skovgaard@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Kjær, Professor</last_name>
    <phone>+35454011</phone>
    <email>andreas.kjaer@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorthe Skovgaard, MD, Phd</last_name>
      <phone>+35455209</phone>
      <email>dorthe.skovgaar@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Kjær</last_name>
      <phone>+35454011</phone>
      <email>andreas.kjaer@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>November 19, 2017</last_update_submitted>
  <last_update_submitted_qc>November 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Dorthe Skovgaard</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>68Ga-NODAGA-E[c(RGDyK)]2</keyword>
  <keyword>Angiogenesis PET/CT</keyword>
  <keyword>Neuroendocrine tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

